Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513934-40-00

Enrollment

400

Registered

2024-11-18

Start date

2019-09-20

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Brief summary

progression free-survival

Detailed description

Overall survival

Interventions

DRUGSELUMETINIB

DRUGCASODEX 50 mg compresse rivestite con film

DRUGOLAPARIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
progression free-survival	—

Secondary

Measure	Time frame
Overall survival	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026